

Gastrointestinal and urinary dysfunctions in late-onset Pompe disease

L. Vercelli, V. Ponzalino, S. Bortolani, T. Mongini

Center for Neuromuscular Diseases, Department of Neuroscience 'Rita Levi Montalcini', University of Turin

INTRODUCTION

Glycogen-storage disease type II (GSD2) or Pompe disease is an hereditary metabolic myopathy caused by deficiency of the lysosomal enzyme acid α -glucosidase. The disease causes lysosomal and cytoplasmic glycogen accumulation in cardiac and skeletal muscles, as well as in various other tissues.

The classical infantile-onset Pompe disease presents with rapidly progressive cardiomyopathy, muscle weakness, and hypotonia before one year of age. Late-onset Pompe disease (LOPD) presents in juvenile or adult life and it is clinically heterogeneous. Symptoms in children and adults with a LOPD presentation are predominantly related to skeletal muscle dysfunction, resulting in both motor and respiratory deficits. LOPD clinical phenotype is heterogeneous and can vary from severe skeletal muscle weakness with respiratory involvement to asymptomatic subjects with isolated serum hyperCKemia. Low tissue levels of acid alpha-glucosidase (GAA) activity (usually in the range of 1-40% of normal) are considered the gold standard for the diagnosis, eventually confirmed by molecular analysis of GAA gene.

Several works, especially from autopsy studies, have demonstrated that glycogen accumulates also in smooth muscle: urinary and gastrointestinal tracts could be involved in this pathology but often these symptoms are not studied and they are underestimated by clinicians as they focus on the motor and respiratory involvement.

AIM OF THE STUDY

The purpose of the study was to evaluate whether LOPD patients have gastrointestinal or urinary interest, in order to assess the clinical spectrum of GSD2 and to determine intestinal and bladder dysfunctions in GSD2 patients which are currently unknown.

METHODS

Patients with LOPD were asked about their symptoms concerning the upper and lower intestinal tract as well as urinary incontinence using the Gastrointestinal Symptoms Questionnaire (GSRs) and the International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI SF). Both questionnaires are available in Italian version and have been validated. The questionnaires are given below (Fig 1 and 2).

RESULTS

Eleven patients with LOPD (6 females, 5 males), all molecular confirmed, were included in our study; the median age was 50.2 years (range 31-79 years of age). All subjects were receiving enzyme replacement therapy (ERT). Clinical features, their onset, pulmonary involvement and ambulatory status are reported in the table (Table 1). They completed GSRs and ICIQ-UI SF Italian validated questionnaires.

The most frequently mentioned symptoms were abdominal distension (81.8%), flatulence (90.9%), sensation of incomplete evacuation (72.7%), Hard stools (45.4%) and constipation (54.5%) were often reported. Diarrhoea was reported by three patients (27.2%), while nausea and vomiting by four subjects (36.3%). It seemed to emerge from the questionnaire that patients often complained about lower intestinal tract disorders than the digestive part. Two women reported severe symptoms of the digestive tract. However we think that they were more related to a psychosomatic disorder as asking patients if they took drugs regularly for these problems they have denied (Table 2).

About bladder dysfunctions, four women out of six reported mild/moderate urinary incontinence with urgency: they referred a small/moderate amount of urine, often before they get to the toilet and/or when they cough or sneeze. Three of them have had physiological pregnancies and deliveries, one female did not have children. A male patient (aged 79) suffered from a severe urinary incontinence but probably secondary to prostate surgical treatment.

DISCUSSION

Glycogen storage within the skeletal muscles as well as in the organs containing the smooth muscle (bladder, intestine, and esophagus) has been demonstrated in autopsy works (Hobson-Webb et al. 2012); these data support the clinical symptoms complained by our GSD2 population.

The GSRs and ICIQ-UI SF questionnaires are simple in compilation, translated into Italian language and can be easily used during clinical evaluation. They could be useful during follow up patients in ERT to evaluate possible beneficial effect on these problems but we cannot rule out that ERT might cause some of these symptoms (excessive intestinal air) as side effects.

Objective measurements (pelvic EMG, anorectal manometry, urodynamic tests, bladder ultrasonography) could be used to confirm these problems.

Symptoms reported by patients did not correlate with their motor deficits, age, treatment duration or with pulmonary involvement. Some Authors have demonstrated similar results in recent studies (Karabul et al 2014, Mc Namara et al 2015).

CONCLUSION

Late-onset glycogen storage disease type 2 is characterized by motor and respiratory involvement; however GSD2 must be considered a systemic disease because accumulation of glycogen can affect other organs, in particular the smooth muscle. Other myopathies, especially muscular and myotonic dystrophy, show evidence of gastrointestinal symptoms and how they can interfere in social, professional and emotional life of the patients. These aspects could lead to disabling conditions in LOPD and their treatments may significantly improve quality of life.

This is a preliminary study which shows that patients complain gastrointestinal symptoms (abdominal distension, flatulence, feeling of incomplete emptying) and even in some females moderate urinary incontinence. These single-center data are preliminary and require a more extensive instrumental evaluation and may be expanded to Italian GSDII Group.

References

- Hobson-Webb LD, Proia AD, Thurberg BL et al. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. *Mol Genet Metab.* 2012;106:462-469
 McNamara ER, Austin S, Case L, Wiener JS, Peterson AC, Kishnani PS. Expanding our understanding of lower urinary tract symptoms and incontinence in adults with Pompe disease. *JIMD Rep.* 2015. Epub 2015 Jan 23.
 Karabul N, Skudlarek A, Berndt J, Kornblum C, Kley RA, Wenninger S, Tiling N, Mengel E, Plöckinger U, Vorgerd M, Deschauer M, Schoser B, Hanisch F. Urge incontinence and gastrointestinal symptoms in adult patients with pompe disease: a cross-sectional survey. *JIMD Rep.* 2014;17:53-61

Figure 1. The Gastrointestinal Symptom Rating Scale Questionnaire (GSRs).

ID pz	Age	Age at onset	Symptom at onset	Start ERT	NIMV	Loss of ambulation
GS	79	50	Myalgias	2006	N	N
BC	48	7	Pelvic weakness	2008	Y + MV	Y
DA	52	29	Pelvic weakness	2008	N	N
DC	52	42	Pelvic weakness	2009	Y	N
RI	42	39	HyperCKemia	2014	N	N
GE	48	42	Limb girdle weakness	2008	N	N
MV	46	34	HyperCKemia	2007 (she stopped during 2014)	N (she refused)	N
PT	57	37	Limb girdle weakness	2007	N	N
ME	59	30	Scapular weakness	2010	N	N
DeC	39	34	Pelvic weakness	2011	Y	N
DIT	31	28	Limb girdle weakness	2015	N	N

Table 1. Clinical features of our LOPD patients

Figure 2. International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI SF)

	Absent	Mild/moderate	Severe
Abdominal pain	+++++	+++	
Heartburn	+++++	+++	+
Acid regurgitation	+++++	++	+
Sucking sensation in the epigastrium	+++++	+++	
Nausea and vomiting	+++++	+++	+
Borborygmus	+++++	++++	
Abdominal distension	++	+++++	++
Eructation	+++++	++++	
Increased flatulence	+	+++++	+
Decreased passage of stools	++++	+++++	
Increased passage of stools	+++++	+++	
Loose stools	+++++	+++	
Hard stools	+++++	++	+++
Urgent need for defecation	+++++	+++	
Feeling of incomplete evacuation	+++	+++++	

Table 2. Gastro-intestinal symptoms reported by GSD2 patients, according to GSRs questionnaire